Solvipurity
ANALYTICAL LABORATORY · REYKJAVÍK, IS

SVP-2026-00283
ISSUED 2026-03-16 · ACCREDITATION AL-1142
ISO/IEC 17025 · GMP · GLP

CERTIFICATE OF ANALYSIS

AUTHENTIC

B7-33 6mg

Björn Healthcare ehf. · Sterile lyophilizate, 6 mg per 3 ml clear glass vial, rubber s topper + aluminium flip-off (white cake)

REPRESENTATIVE CHROMATOGRAM · HPLC-UV 205 NM



BATCH NO.
BJRN-209Q96T

ANALYTICAL METHODS
RP-HPLC-UV 220 nm · LC-ESI-MS · AAA (amino acid analysis) · Ion chromatography (counter-ion) · Karl Fischer 2.5.32 · GC-MS (headspace) · ICP-MS · Kinetic chromogenic LAL 2.6.14 · Ph. Eur. 2.6.1 sterility · Ph. Eur. 2.6.12 microbial limits

MANUFACTURED
2026-02-12

EXPIRY
2027-11-12

RECEIVED
2026-03-16

RELEASE
2026-03-16

DECLARED COMPOSITION
B7-33 6mg — synthetic peptide; sequence: relaxin-2 B-chain single-chain analog (33 aa); CAS n/a; theoretical MW 3251.70 Da

Analytical results

19 TESTS · ALL METHODS VALIDATED

SUBSTANCE / PARAMETER	RESULT	LOQ	LIMIT	METHOD
Appearance — sterile lyophilized cake, white to off-white	**Conforms**	—	homogeneous white cake, no particulates	Visual
Solubility (water for injection, 2 mg/ml, 25 °C)	**Complete within 60 s — clear colourless solution**	—	Clear, no visible particles	Visual (Ph. Eur. 2.2.1)

Identification — HPLC retention time	**Matches reference**	—	±2.0 % of ref	RP-HPLC-UV 220 nm
Identification — sequence / mass match	**Confirmed** CAS n/a	—	Match theoretical within ±1 Da	LC-ESI-MS
Molecular weight (measured)	**3251.54 Da** Δ = -0.16 Da	0.5 Da	3251.70 Da ± 1.0 Da (theoretical)	ESI-MS
Chromatographic purity (main peak)	**99.35 %**	0.05 %	≥ 98.0 %	RP-HPLC-UV 220 nm
Any single impurity (max)	**0.23 %**	0.05 %	≤ 1.00 %	RP-HPLC-UV 220 nm
Peptide content (amino acid analysis)	**86.8 % w/w**	0.5 %	≥ 80.0 % w/w	AAA (6 N HCl, 110 °C, 24 h)
Trifluoroacetate (TFA counter-ion)	**0.38 % w/w**	0.05 %	≤ 1.00 % w/w	IC (ion chromatography)
Water content (Karl Fischer)	**3.55 % w/w**	0.1 %	≤ 5.0 % w/w	Ph. Eur. 2.5.32
Residual acetonitrile	**166 ppm**	10 ppm	≤ 410 ppm (ICH Q3C Class 2)	GC-MS (headspace)
Residual DMF	**55 ppm**	10 ppm	≤ 880 ppm (ICH Q3C Class 2)	GC-MS (headspace)
Lead (Pb)	**0.032 ppm**	0.02 ppm	≤ 0.5 ppm (ICH Q3D parenteral)	ICP-MS
Arsenic + Cadmium + Mercury (total)	**0.172 ppm**	0.02 ppm	≤ 1.5 ppm (ICH Q3D parenteral)	ICP-MS
Bacterial endotoxins (LAL)	**2.93 EU/mg**	0.125 EU/mg	< 10.0 EU/mg	Kinetic chromogenic LAL (Ph. Eur. 2.6.14)
TAMC (aerobic bacteria, pre-lyophilization bulk)	**8 CFU/g**	1 CFU/g	≤ 10^2 CFU/g	Ph. Eur. 2.6.12
TYMC (yeast / molds, pre-lyophilization bulk)	**3 CFU/g**	1 CFU/g	≤ 10^1 CFU/g	Ph. Eur. 2.6.12
Sterility (final lyophilized vial)	**Complies — no growth**	—	No growth, 14 d incubation	Ph. Eur. 2.6.1 (direct inoculation)
Container closure integrity	**Pass**	—	No dye uptake	Dye ingress (0.05 % methylene blue, 2 h vacuum)

INDEPENDENT VERIFICATION

Verify this certificate

Scan the QR or visit the URL and enter the 6-character code.
Everything on this printed copy must match the online record exactly.
Any discrepancy means the document has been tampered with.

solvipurity.com/pl/verify/result?id=SVP-2026-00283&code=RKFFHX

RKFFHX

VERIFICATION CODE

ANALYST
dr Sigurður Pálsson
Senior chemist

INDEPENDENT REVIEWER
dr Helga Thorgeirsdottir
Quality assurance · AL-1142

SHA-256 CHECKSUM
0-xa8cc93dc735ce3f4a8cc93dc735ce3f4a8cc93dc735ce3f4
Tamper-evident digest

NOTICE · CONDITIONS OF THIS REPORT

This certificate of analysis applies exclusively to the sample received and described above. It does not constitute approval, endorsement or certification of the product or its intended use. Results were obtained under ISO/IEC 17025 accredited methods by Solvipurity ehf. (accreditation AL-1142). Reproduction of this document in part is prohibited — only the full, verified copy may be shared. If the data printed here does not match the online record at solvipurity.com/verify, the document should be considered invalid.

SAMPLE RETENTION

Sealed aliquot retained for 24 months from issue date under controlled conditions (Ph. Eur. 5.1, −20 °C).

DISPUTE WINDOW

Requests for re-testing accepted within 30 days of report publication. Contact lab@solvipurity.com quoting the report number.